COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts Organ preservation has become an attractive alternative to ...

Many patients with locally advanced rectal cancer treated with total neoadjuvant therapy in the OPRA trial achieved a complete or near-complete tumor response and were initially offered a ...

SAN FRANCISCO -- More than half of patients with higher-risk rectal cancer avoided aggressive surgery for at least 2 years following short-course radiation therapy (RT) and chemotherapy consolidation, ...

Patients with localized rectal cancer classified as low risk can skip neoadjuvant chemoradiotherapy (nCRT) with an acceptably low risk of local relapse, new research suggests. A prospective study of ...

TNT achieved a 93.7% complete response rate and 87.5% organ preservation in stage I rectal cancer patients. TNT may offer an organ-preserving alternative to surgery, especially for low-lying tumors, ...

One major challenge lies within the solid tumor microenvironment (TME), where immunosuppressive cytokines can hinder the tumor-killing activity of T-cells. As a result, the TME plays a critical role ...